Lilly Asia Ventures co-leads $100M+ round for Chinese biotech and its late-stage lupus drug
Can a Chinese biotech deliver the first new lupus drug in decades? A high-profile group of VCs are betting on it.
Lilly Asia Ventures and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
